IntraCellular Therapies (ITCI)
(Delayed Data from NSDQ)
$73.26 USD
+1.13 (1.57%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $73.35 +0.09 (0.12%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ITCI 73.26 +1.13(1.57%)
Will ITCI be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ITCI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ITCI
Will Intra-Cellular Therapies (ITCI) Report Negative Q1 Earnings? What You Should Know
Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success
ITCI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Intra-Cellular (ITCI) Up as Depression Drug Meets Study Goals
Intra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last?
Intra-Cellular (ITCI) Q4 Loss Narrower Than Expected, Sales Miss
Other News for ITCI
Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
3 Biotech Stocks With Skyrocketing Potential: April 2024
Analysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and Intra-Cellular Therapies (ITCI)
Intra-Cellular price target raised by $7 at Canaccord, here's why
Buy Rating on Intra-Cellular Therapies as Caplyta Shows Promise in Major Depressive Disorder Market